SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001610618-24-000065
Filing Date
2024-04-30
Accepted
2024-04-30 16:10:49
Documents
1
Period of Report
2024-04-24

Document Format Files

Seq Description Document Type Size
1 FORM 3 wk-form3_1714507830.html 3  
1 FORM 3 wk-form3_1714507830.xml 3 1575
  Complete submission text file 0001610618-24-000065.txt   3197
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Issuer) CIK: 0001610618 (see all company filings)

IRS No.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O DYNAVAX TECHNOLOGIES CORPORATION 2929 SEVENTH STREET, SUITE 100 BERKELEY CA 94710-2753
Business Address
Spencer Ryan (Reporting) CIK: 0001777938 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-36912 | Film No.: 24897270